To bypass the acquired drug resistance to TKIs, the use of siRNA-based approaches has been proposed by Chen et al. Authors demonstrated that co-administering TKIs with an anti-EGFR siRNA increases the apoptotic rate in different NSCLC lines [101]. Here, EGFR is linked to non-small cell lung carcinoma.